Search
forResearch 8 of 595
- A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
- Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Effect of High Levels of Testosterone on Cardiovascular Risk in Polycystic Ovary Syndrome (PCOS)
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →